Dead on arrival

ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Retrieved on: 
Monday, October 30, 2023
Neoplasm, FDA, Food, Therapy, Breakthrough, R&D, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Breakthrough therapy, Dead on arrival, Safety, Patient, EGFR, Pharmaceutical industry, NSCLC

“Breakthrough Therapy designation is an important step forward in our development of furmonertinib and highlights its exciting potential as a first-line therapy for patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations,” said Bing Yao, Chairman, Co-founder and Chief Executive Officer of ArriVent.

Key Points: 
  • “Breakthrough Therapy designation is an important step forward in our development of furmonertinib and highlights its exciting potential as a first-line therapy for patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations,” said Bing Yao, Chairman, Co-founder and Chief Executive Officer of ArriVent.
  • Stuart Lutzker, Co-founder and President of R&D added: “This FDA designation underscores the encouraging clinical activity we have seen with furmonertinib in the FAVOUR study and reflects the critical need for effective and tolerable therapeutic options for these patients.
  • Interim results from the trial demonstrated furmonertinib has promising anti-tumor activity as a single agent with a well-tolerated safety profile in the first-line and previously treated patients.
  • The pivotal Phase 3 FURVENT trial (NCT05607550) of furmonertinib for the treatment of first-line NSCLC with EGFR exon 20 insertion mutations is currently enrolling patients globally.

Allist and ArriVent Announce Interim Results from Ongoing Phase 1b Trial with Furmonertinib at the 2023 World Conference on Lung Cancer

Retrieved on: 
Sunday, September 10, 2023
WCLC, IRC, Diarrhea, Dead on arrival, Lung cancer, Trae tha Truth, International Association, NSCLC, Patient, EGFR, Phases of clinical research, Anemia, Corr, Shanghai Chest Hospital, Conference, Safety, Pharmaceutical industry

The median duration of response were 15.2 months, 13.1 months, and 9.7 months in the treatment-naïve 240 mg, previously treated 240 mg, and previously treated 160 mg patient groups, respectively.

Key Points: 
  • The median duration of response were 15.2 months, 13.1 months, and 9.7 months in the treatment-naïve 240 mg, previously treated 240 mg, and previously treated 160 mg patient groups, respectively.
  • Anti-tumor responses were observed across near-loop, far-loop and helical EGFR exon 20 insertion mutations.
  • A well-tolerated safety profile has been observed to-date in the FAVOUR study.
  • The trial is currently enrolling patient in the US, China and other countries.

InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib

Retrieved on: 
Thursday, September 14, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, HER2, Clinical trial, DLT, Cancer, Dead on arrival, Lung cancer, NSCLC, SHP2, SSE, HKEX, Investigational New Drug, Cervical cancer, Patient, SRC, EGFR, Entrepreneurship, IND, Pharmaceutical industry

Furmonertinib is being advanced by ArriVent in global studies in patients with advanced or metastatic NSCLC with EGFR or HER2 mutations, including exon 20 insertion mutations and other uncommon EGFR mutations.

Key Points: 
  • Furmonertinib is being advanced by ArriVent in global studies in patients with advanced or metastatic NSCLC with EGFR or HER2 mutations, including exon 20 insertion mutations and other uncommon EGFR mutations.
  • ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed by InnoCare for the treatment of solid tumors as a single agent and/or in combination with other antitumor agents.
  • Dr. Jasmine Cui, Co-Founder, Chairwoman and CEO of InnoCare, said: “SHP2 inhibitor is an ideal partner for combination with multiple targeted and immune-oncology therapies in the field of solid tumor.
  • We will work with ArriVent to accelerate clinical development of the combination of ICP-189 and furmonertinib, so that this innovative therapy can benefit patients with advanced NSCLC earlier."

InnoCare and ArriVent Announce Clinical Development Collaboration

Retrieved on: 
Friday, July 14, 2023
PK, Therapy, HER2, Cancer, Dead on arrival, Lung cancer, NSCLC, SHP2, SSE, HKEX, SRC, Patient, EGFR, Safety, Pharmaceutical industry

Furmonertinib is being advanced by ArriVent in global studies in patients with advanced or metastatic NSCLC with EGFR or HER2 mutations, including exon 20 insertion mutations.

Key Points: 
  • Furmonertinib is being advanced by ArriVent in global studies in patients with advanced or metastatic NSCLC with EGFR or HER2 mutations, including exon 20 insertion mutations.
  • Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said: “NSCLC is the major subtype of lung cancer with huge unmet medical needs.
  • We are glad to work with ArriVent to push forward the combination study and expect this innovative therapy to benefit global patients early.”
    “We are excited to announce this clinical development collaboration with InnoCare,” said Bing Yao, Ph.D., Chairman, Co-founder and Chief Executive Officer of ArriVent.
  • “Combining furmonertinib with ICP-189 represents the growing opportunity for our furmonertinib clinical development program, in addition to ongoing studies in the monotherapy setting.

ArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR or HER2 Mutations

Retrieved on: 
Tuesday, July 5, 2022
Review, FDA, Patient, Brain, EGFR, GLOBE, Man, Disease, NSCLC, Lung cancer, Non-small-cell lung carcinoma, Mutation, Pharmacokinetics, Fast Track, HER2, Woman, Food, Therapy, Communication, Plasma protein binding, Dead on arrival, Drug development, Safety, Point mutation, Stage 2, Dose, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

NEWTOWN SQUARE, Pa., July 05, 2022 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the first patient has been enrolled in its Phase 1b trial of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) or HER2 mutations, including exon 20 insertion mutations. Furmonertinib, an oral, irreversible, pan-EGFR mutant selective inhibitor—which has been shown to be highly brain penetrant—was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) in this indication.

Key Points: 
  • Furmonertinib is approved in China as an anticancer therapy for EGFR T790M NSCLC patients, and more recently, as a first-line treatment for classical EGFR mutant NSCLC patients.
  • Furmonertinib is being developed in China by Allist Pharmaceuticals and in the rest of the world by ArriVent Biopharma.
  • Non-small cell lung cancer (NSCLC) is the predominant subtype of lung cancer, accounting for approximately 85% of all cases.
  • 31% of EGFR activating mutations are termed atypical EGFR mutations of which exon 20 insertion mutations constitute 9% of EGFR activating mutations overall.

RevSpring Announces New Campaign Messaging to Activate Patient Response Prior to Service

Retrieved on: 
Tuesday, June 14, 2022
Omnichannel, EHR, Efficiency, Patient, Goal, Dead on arrival, Communication, Health insurance, Public relations, Mail, Healthcare

NASHVILLE, Tenn., June 14, 2022 /PRNewswire-PRWeb/ -- RevSpring, the leading provider of healthcare engagement and payment solutions, today announced new campaign functionality that empowers healthcare providers to easily and effectively tailor multi-touch campaigns for select patient groups, with personalized messages designed to inspire individualized actions to prepare for service.

Key Points: 
  • Campaign messaging is a major expansion of RevSpring's preservice suite, including the Arrived visit management platform and Talksoft patient messaging and appointment reminders.
  • New multi-touch campaign capabilities proactively reach patients via phone, text or email, and now include additional features and staff-facing tools to manage and distribute campaigns.
  • "Our new campaigns functionality moves RevSpring's patient communication to an even more personalized level while maintaining the efficiency of group outreach," said Steve David, vice president, patient messaging at RevSpring.
  • RevSpring leads the market in patient engagement and payment solutions that inspire patients to participate in and pay for their healthcare.

With Fentanyl-Laced Drug Overdoses Running Rampant Across the U.S., SMILEZ Digs Deep into His Personal Struggle via New Video

Retrieved on: 
Friday, December 10, 2021
CDC, Fentanyl, Illegal drug trade, Administration, Juice Wrld, MUSIC, Motivation, Parent, Culture, Music, VOID, Drug, Sudden death, LINK, Social media, Partnership, Education, Awareness, Dead on arrival, Entertainment

"SMILEZ music video brought tears to my eyes," said Bill Bodner, Head of the Drug Enforcement Administration - Los Angeles.

Key Points: 
  • "SMILEZ music video brought tears to my eyes," said Bill Bodner, Head of the Drug Enforcement Administration - Los Angeles.
  • "Showing real footage of him [SMILEZ] carrying his brother's baby at his funeral really shows how damaging these drugs can be to families."
  • "If Fentanyl was gone, SMILEZ brother, my son, and thousands of others would still be amongst us.
  • With SMILEZ being a creative and immersed in social media culture, they plan to develop educational content together that will resonate to the masses.